Studies on bis(vanillin)benzidine complexes of titanium(III), vanadium(III), iron(III), manganese(II), cobalt(II) and nickel(II)

79-82The complexes of bis(vanillin)benzidine,(vn2bz)of the type [M(vn2bz)(H2O)2CI2]2CI2[where M=Ti(III), V(III) and Fe(III)] and [M(vn2bz)(H2O)Cl]2CI2 [where M= Mn(II),Co(II) and Ni(II)] have been synthesized and characterized on the basis of elemental analyses, molar conductances, thermogravimetric analyses,magnetic moments, infrared and electronic spectra. The ligand vn2bz has six coordination sites. The phenolic OH group (remains unionized) and the methoxy groups do not take part in coordination and remain forbidden sites. Only azomethine nitrogens take part in coordination. Thus: the ligand bis(vanillin) benzidine acts as a nonfunctional bidentate cbelating agent. The complexes of titanium(III), vanadium(III), and iron(III) are found to be hexa-coordinate octahedral, whereas manganese(II),cobalt(II), and nickel(II) complexes are tetra-coordinate tetrahedral

Studies on Bis(p-dimethylaminobenzyl-idene)benzidine Complexes of Trivalent Lanthanides

589-59

Trivalent Lanthanide Complexes of Schiff Base Derived from Acetylacetone & Benzidine

259-26

Bis(benzylidene)benzidine Complexes of Cr(III), Mn(II), Fe(III), Co(II) & Ni(II)

170-17

Lessons learned from the eMERGE Network: balancing genomics in discovery and practice

The Electronic Medical Records and Genomics (eMERGE) Network, established in 2007, is a consortium of academic and integrated health systems conducting discovery and implementation research in translational genomics. Here, we outline the history of the network, highlight major impacts and lessons learned, and present the tools and resources developed for large-scale genomic analyses and translation into a clinical setting. The network developed methods to extract phenotypes from the electronic medical record to perform genome-wide and phenome-wide association studies. Recruited cohorts were clinically sequenced off a custom panel for targeted sequencing of variants and monogenic disease risks and returned to participants to investigate the impact of return of genomic results. After generating a 105,000 participant-imputed genome-wide association study (GWAS) dataset for discovery, the network enrolled and sequenced 24,998 participants. Integration of these results into the medical record and the effects of results on participants provided key lessons to the field. These learned lessons inform genetic research in diverse populations and provide insights into the clinical impact of return and implementation of genomic medicine using the electronic medical record. The lessons produced by the eMERGE Network can be utilized by other consortia as translational genomic medicine research evolves